Spero Therapeutics, Inc.SPRONASDAQ
LOADING
|||
Switch Symbol:
Operating Income Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year operating income growth rate
Latest
-223.90%
↓ 430% below average
Average (36q)
67.91%
Historical baseline
Range
High:2712.82%
Low:-223.90%
Volatility
4324.1%
High variability
| Period | Value |
|---|---|
| Q3 2025 | -223.90% |
| Q2 2025 | 83.41% |
| Q1 2025 | 32.19% |
| Q4 2024 | -16.85% |
| Q3 2024 | 2.46% |
| Q2 2024 | -36.33% |
| Q1 2024 | -127.67% |
| Q4 2023 | 2712.82% |
| Q3 2023 | 85.00% |
| Q2 2023 | 9.40% |
| Q1 2023 | -154.88% |
| Q4 2022 | 319.06% |
| Q3 2022 | 54.62% |
| Q2 2022 | 13.66% |
| Q1 2022 | -9.84% |
| Q4 2021 | -22.10% |
| Q3 2021 | -21.48% |
| Q2 2021 | 4.44% |
| Q1 2021 | -3.23% |
| Q4 2020 | 1.18% |
| Q3 2020 | -2.94% |
| Q2 2020 | 19.04% |
| Q1 2020 | 11.83% |
| Q4 2019 | -43.91% |
| Q3 2019 | -31.74% |
| Q2 2019 | -139.68% |
| Q1 2019 | 48.61% |
| Q4 2018 | -1.36% |
| Q3 2018 | -9.67% |
| Q2 2018 | 7.81% |
| Q1 2018 | 22.74% |
| Q4 2017 | -40.48% |
| Q3 2017 | 1.96% |
| Q2 2017 | -33.77% |
| Q1 2017 | 13.75% |
| Q4 2016 | -11.32% |
| Q3 2016 | 0.00% |